Cagrilintide vs Retatrutide

Cagrilintide

Cagrilintide is a long-acting acylated amylin analogue engineered for extended receptor engagement at the amylin receptor complex (AMY1 and AMY3). Its mechanism involves activating calcitonin and amylin receptors in the area postrema and hypothalamus, modulating satiety signaling and gastric emptying. In the REDEFINE 1 phase 3 trial (Lau et al., published 2023), cagrilintide 2.4 mg administered weekly demonstrated statistically significant weight reduction compared to placebo over 68 weeks. Notably, Novo Nordisk's CagriSema program combines cagrilintide with semaglutide, and phase 2 data (REDEFINE 2) showed the combination achieved greater weight reduction than either agent alone, suggesting synergistic effects between amylin and GLP-1 receptor pathways. Compared to pramlintide, the only previously available amylin analogue, cagrilintide offers a substantially longer half-life (approximately 7 days vs. hours), enabling once-weekly dosing in research protocols. Research also indicates potential benefits in alcohol-related liver disease models, where amylin signaling may reduce hepatic lipid accumulation. The lyophilized powder should be stored at -20C prior to reconstitution with sterile water or bacteriostatic water; reconstituted solutions should be refrigerated at 2-8C. This compound is primarily studied by obesity research institutes, pharmaceutical laboratories investigating incretin-amylin synergy, and academic centers focused on appetite neurobiology and hepatic metabolism.

Retatrutide

Retatrutide is a first-in-class triple-agonist peptide that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Its mechanism of action involves binding all three receptor systems to modulate appetite signaling, glucose homeostasis, and energy expenditure through complementary metabolic pathways. In a phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants receiving 12 mg of retatrutide achieved a mean body weight reduction of approximately 24.2% at 48 weeks, surpassing results observed with dual-agonist compounds like tirzepatide. The glucagon receptor component is believed to contribute additional energy expenditure and hepatic lipid metabolism benefits not seen with GLP-1-only or GIP/GLP-1 dual agonists. Compared to semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1 dual), retatrutide represents an expansion of the incretin-based approach by incorporating glucagon receptor activation, which studies suggest enhances thermogenesis and fat oxidation. For research use, the lyophilized powder should be stored at -20C and reconstituted with bacteriostatic water immediately before use; reconstituted solutions remain stable under refrigeration at 2-8C for up to 28 days. This compound is primarily investigated by academic metabolic research centers, pharmaceutical R&D divisions, and endocrinology laboratories studying multi-receptor agonism as a strategy for metabolic syndrome research.

Frequently Asked Questions